Skip to main content
Erschienen in: Breast Cancer Research and Treatment 3/2017

08.12.2016 | Epidemiology

Association between adjuvant chemotherapy and risk of acute kidney injury in elderly women diagnosed with early-stage breast cancer

verfasst von: Shuling Li, Jiannong Liu, Beth A. Virnig, Allan J. Collins

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

We studied elderly Medicare enrollees newly diagnosed with early-stage breast cancer to examine the association between adjuvant chemotherapy and acute kidney injury (AKI).

Methods

Using the linked Surveillance, Epidemiology, and End Results (SEER)-Medicare database, we conducted a retrospective cohort study including women diagnosed with stages I–III breast cancer at ages 66–89 years between 1992 and 2007. We performed one-to-one matching on time-dependent propensity score on the day of adjuvant chemotherapy initiation within 6 months after the first cancer-directed surgery based on the estimated probability of chemotherapy initiation at each day for each patient, using a Cox proportional hazards model. We estimated the cumulative incidence of AKI using Kaplan–Meier methods. We used Cox proportional hazards models to evaluate the association between chemotherapy and the risk of AKI, and compared the risk among major chemotherapy types.

Results

The study included 28,048 women. The 6-month cumulative incidence of AKI was 0.80% for chemotherapy-treated patients, compared with 0.30% for untreated patients (P < 0.001). Adjuvant chemotherapy was associated with a nearly threefold increased risk of AKI [hazard ratio (HR) 2.73; 95% CI 1.8–4.1]. Compared with anthracycline-based chemotherapy, the HRs (95% CIs) were 1.66 (0.94–2.91), 0.88 (0.53–1.47), and 1.15 (0.57–2.32) for taxane-based, CMF, and other chemotherapy, respectively.

Conclusion

Our findings showed that adjuvant chemotherapy was associated with increased risk of AKI in elderly women diagnosed with early-stage breast cancer. The risk seemed to vary by regimen type, but the differences were not statistically significant.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
3.
Zurück zum Zitat Cole BF, Gelber RD, Gelber S, Coates AS, Goldhirsch A (2001) Polychemotherapy for early breast cancer: an overview of the randomised clinical trials with quality-adjusted survival analysis. Lancet 358:277–286CrossRefPubMed Cole BF, Gelber RD, Gelber S, Coates AS, Goldhirsch A (2001) Polychemotherapy for early breast cancer: an overview of the randomised clinical trials with quality-adjusted survival analysis. Lancet 358:277–286CrossRefPubMed
4.
Zurück zum Zitat Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717CrossRef Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717CrossRef
6.
Zurück zum Zitat Ali T, Khan I, Simpson W, Prescott G, Townend J, Smith W, Macleod A (2007) Incidence and outcomes in acute kidney injury: a comprehensive population-based study. J Am Soc Nephrol 18:1292–1298CrossRefPubMed Ali T, Khan I, Simpson W, Prescott G, Townend J, Smith W, Macleod A (2007) Incidence and outcomes in acute kidney injury: a comprehensive population-based study. J Am Soc Nephrol 18:1292–1298CrossRefPubMed
7.
Zurück zum Zitat Salahudeen AK, Doshi SM, Pawar T, Nowshad G, Lahoti A, Shah P (2013) Incidence rate, clinical correlates, and outcomes of AKI in patients admitted to a comprehensive cancer center. Clin J Am Soc Nephrol 8:347–354CrossRefPubMed Salahudeen AK, Doshi SM, Pawar T, Nowshad G, Lahoti A, Shah P (2013) Incidence rate, clinical correlates, and outcomes of AKI in patients admitted to a comprehensive cancer center. Clin J Am Soc Nephrol 8:347–354CrossRefPubMed
8.
Zurück zum Zitat Samuels J, Ng CS, Nates J, Price K, Finkel K, Salahudeen A, Shaw A (2011) Small increases in serum creatinine are associated with prolonged ICU stay and increased hospital mortality in critically ill patients with cancer. Support Care Cancer 19:1527–1532CrossRefPubMed Samuels J, Ng CS, Nates J, Price K, Finkel K, Salahudeen A, Shaw A (2011) Small increases in serum creatinine are associated with prolonged ICU stay and increased hospital mortality in critically ill patients with cancer. Support Care Cancer 19:1527–1532CrossRefPubMed
9.
Zurück zum Zitat Perazella MA, Moeckel GW (2010) Nephrotoxicity from chemotherapeutic agents: clinical manifestations, pathobiology, and prevention/therapy. Semin Nephrol 30:570–581CrossRefPubMed Perazella MA, Moeckel GW (2010) Nephrotoxicity from chemotherapeutic agents: clinical manifestations, pathobiology, and prevention/therapy. Semin Nephrol 30:570–581CrossRefPubMed
10.
Zurück zum Zitat Liu LL, Li QX, Xia L, Li J, Shao L (2007) Differential effects of dihydropyridine calcium antagonists on doxorubicin-induced nephrotoxicity in rats. Toxicology 231:81–90CrossRefPubMed Liu LL, Li QX, Xia L, Li J, Shao L (2007) Differential effects of dihydropyridine calcium antagonists on doxorubicin-induced nephrotoxicity in rats. Toxicology 231:81–90CrossRefPubMed
11.
Zurück zum Zitat Mohan M, Kamble S, Gadhi P, Kasture S (2010) Protective effect of Solanum torvum on doxorubicin-induced nephrotoxicity in rats. Food Chem Toxicol 48:436–440CrossRefPubMed Mohan M, Kamble S, Gadhi P, Kasture S (2010) Protective effect of Solanum torvum on doxorubicin-induced nephrotoxicity in rats. Food Chem Toxicol 48:436–440CrossRefPubMed
12.
Zurück zum Zitat Stankiewicz A, Skrzydlewska E (2003) Protection against cyclophosphamide-induced renal oxidative stress by amifostine: the role of antioxidative mechanisms. Toxicol Mech Methods 13:301–308CrossRefPubMed Stankiewicz A, Skrzydlewska E (2003) Protection against cyclophosphamide-induced renal oxidative stress by amifostine: the role of antioxidative mechanisms. Toxicol Mech Methods 13:301–308CrossRefPubMed
13.
Zurück zum Zitat Ayhanci A, Gunes S, Sahinturk V, Appak S, Uyar R, Cengiz M, Altuner Y, Yaman S (2010) Seleno l-methionine acts on cyclophosphamide-induced kidney toxicity. Biol Trace Elem Res 136:171–179CrossRefPubMed Ayhanci A, Gunes S, Sahinturk V, Appak S, Uyar R, Cengiz M, Altuner Y, Yaman S (2010) Seleno l-methionine acts on cyclophosphamide-induced kidney toxicity. Biol Trace Elem Res 136:171–179CrossRefPubMed
14.
Zurück zum Zitat Lankelma J, van der Klein E, Ramaekers F (1980) The role of 7-hydroxymethotrexate during methotrexate anti-cancer therapy. Cancer Lett 9:133–142CrossRefPubMed Lankelma J, van der Klein E, Ramaekers F (1980) The role of 7-hydroxymethotrexate during methotrexate anti-cancer therapy. Cancer Lett 9:133–142CrossRefPubMed
15.
Zurück zum Zitat Smeland E, Fuskevag OM, Nymann K, Svendesn JS, Olsen R, Lindal S, Bremnes RM, Aarbakke J (1996) High-dose 7-hydromethotrexate: acute toxicity and lethality in a rat model. Cancer Chemother Pharmacol 37:415–422CrossRefPubMed Smeland E, Fuskevag OM, Nymann K, Svendesn JS, Olsen R, Lindal S, Bremnes RM, Aarbakke J (1996) High-dose 7-hydromethotrexate: acute toxicity and lethality in a rat model. Cancer Chemother Pharmacol 37:415–422CrossRefPubMed
16.
17.
Zurück zum Zitat Burke JF Jr, Laucius JF, Brodovsky HS, Soriano RZ (1977) Doxorubicin hydrochloride-associated renal failure. Arch Intern Med 137:385–388CrossRefPubMed Burke JF Jr, Laucius JF, Brodovsky HS, Soriano RZ (1977) Doxorubicin hydrochloride-associated renal failure. Arch Intern Med 137:385–388CrossRefPubMed
18.
Zurück zum Zitat Seideman P, Muller-Suur R, Ekman E (1993) Renal effects of low dose methotrexate in rheumatoid arthritis. J Rheumatol 20:1126–1128PubMed Seideman P, Muller-Suur R, Ekman E (1993) Renal effects of low dose methotrexate in rheumatoid arthritis. J Rheumatol 20:1126–1128PubMed
19.
20.
Zurück zum Zitat Merouani A, Davidson SA, Schrier RW (1997) Increased nephrotoxicity of combination taxol and cisplatin chemotherapy in gynecologic cancers as compared to cisplatin alone. Am J Nephrol 17:53–58CrossRefPubMed Merouani A, Davidson SA, Schrier RW (1997) Increased nephrotoxicity of combination taxol and cisplatin chemotherapy in gynecologic cancers as compared to cisplatin alone. Am J Nephrol 17:53–58CrossRefPubMed
23.
Zurück zum Zitat Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF (2002) Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 40:3–18 Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF (2002) Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 40:3–18
24.
Zurück zum Zitat Hebert PL, Geiss LS, Tierney EF, Engelgau MM, Yawn BP, McBean AM (1999) Identifying persons with diabetes using Medicare claims data. Am J Med Qual 14:270–277CrossRefPubMed Hebert PL, Geiss LS, Tierney EF, Engelgau MM, Yawn BP, McBean AM (1999) Identifying persons with diabetes using Medicare claims data. Am J Med Qual 14:270–277CrossRefPubMed
25.
Zurück zum Zitat Xu R, Luo Y, Glynn R, Johnson D, Jones KL, Chambers C (2014) Time-dependent propensity score for assessing the effect of vaccine exposure on pregnancy outcomes through pregnancy exposure cohort studies. Int J Environ Res Public Health 11:3074–3085CrossRefPubMedPubMedCentral Xu R, Luo Y, Glynn R, Johnson D, Jones KL, Chambers C (2014) Time-dependent propensity score for assessing the effect of vaccine exposure on pregnancy outcomes through pregnancy exposure cohort studies. Int J Environ Res Public Health 11:3074–3085CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Lu B (2005) Propensity score matching with time-dependent covariates. Biometric 61:721–728CrossRef Lu B (2005) Propensity score matching with time-dependent covariates. Biometric 61:721–728CrossRef
27.
Zurück zum Zitat Austin PC, Grootendorst P, Anderson GM (2007) A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study. Stat Med 26:734–753CrossRefPubMed Austin PC, Grootendorst P, Anderson GM (2007) A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study. Stat Med 26:734–753CrossRefPubMed
28.
Zurück zum Zitat Lin D, Wei L (1989) The robust inference for the Cox proportional hazards model. J Am Stat Assoc 84:1074–1078CrossRef Lin D, Wei L (1989) The robust inference for the Cox proportional hazards model. J Am Stat Assoc 84:1074–1078CrossRef
29.
Zurück zum Zitat Rosenbaum PR, Rubin DB (1985) Constructing a control group using multivariate matched sampling methods that incorporate the propensity score. Am Stat 39:33–38 Rosenbaum PR, Rubin DB (1985) Constructing a control group using multivariate matched sampling methods that incorporate the propensity score. Am Stat 39:33–38
30.
Zurück zum Zitat Austin PC (2008) A critical appraisal of propensity-score matching in the medical literature between 1996 and 2003. Stat Med 27:2037–2049CrossRefPubMed Austin PC (2008) A critical appraisal of propensity-score matching in the medical literature between 1996 and 2003. Stat Med 27:2037–2049CrossRefPubMed
31.
Zurück zum Zitat Du XL, Osborne C, Goodwin JS (2002) Population-based assessment of hospitalizations for toxicity from chemotherapy in older women with breast cancer. J Clin Oncol 20:4636–4642CrossRefPubMedPubMedCentral Du XL, Osborne C, Goodwin JS (2002) Population-based assessment of hospitalizations for toxicity from chemotherapy in older women with breast cancer. J Clin Oncol 20:4636–4642CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat National Comprehensive Cancer Network Clinical Practice Guidelines (2011) Myeloid growth factors Version 1. JNCCN 9:914–932 National Comprehensive Cancer Network Clinical Practice Guidelines (2011) Myeloid growth factors Version 1. JNCCN 9:914–932
33.
Zurück zum Zitat Darmon M, Ciroldi M, Thiery G, Schlemmer B, Azoulay E (2006) Clinical review: specific aspects of acute renal failure in cancer patients. Crit Care 10:211CrossRefPubMedPubMedCentral Darmon M, Ciroldi M, Thiery G, Schlemmer B, Azoulay E (2006) Clinical review: specific aspects of acute renal failure in cancer patients. Crit Care 10:211CrossRefPubMedPubMedCentral
35.
Zurück zum Zitat Langeberg WJ, O’Malley CD, Critchlow CW, Fryzek JP (2009) Risk of acute renal failure among breast cancer patients and chemotherapy treatment of breast cancer patients with a history of renal insufficiency in a commercially-insured population in the United States. J Clin Oncol 27(15Suppl):e22104 [Abstract] Langeberg WJ, O’Malley CD, Critchlow CW, Fryzek JP (2009) Risk of acute renal failure among breast cancer patients and chemotherapy treatment of breast cancer patients with a history of renal insufficiency in a commercially-insured population in the United States. J Clin Oncol 27(15Suppl):e22104 [Abstract]
36.
Zurück zum Zitat Merouani A, Shpall EJ, Jones RB, Archer PG, Schrier RW (1996) Renal function in high dose chemotherapy and autologous hematopoietic cell support treatment for breast cancer. Kidney Int 50:1026–1031CrossRefPubMed Merouani A, Shpall EJ, Jones RB, Archer PG, Schrier RW (1996) Renal function in high dose chemotherapy and autologous hematopoietic cell support treatment for breast cancer. Kidney Int 50:1026–1031CrossRefPubMed
37.
Zurück zum Zitat Jones S, Holmes FA, O’Shaughnessy J, Blum JL, Vukelja SJ, McIntyre KJ et al (2009) Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US oncology research trial 9735. J Clin Oncol 27:1177–1183CrossRefPubMed Jones S, Holmes FA, O’Shaughnessy J, Blum JL, Vukelja SJ, McIntyre KJ et al (2009) Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US oncology research trial 9735. J Clin Oncol 27:1177–1183CrossRefPubMed
38.
Zurück zum Zitat Giordano SH, Lin YL, Kuo YF, Hortobagyi GN, Goodwin JS (2012) Decline in the use of anthracyclines for breast cancer. J Clin Oncol 30:2232–2239CrossRefPubMedPubMedCentral Giordano SH, Lin YL, Kuo YF, Hortobagyi GN, Goodwin JS (2012) Decline in the use of anthracyclines for breast cancer. J Clin Oncol 30:2232–2239CrossRefPubMedPubMedCentral
39.
Zurück zum Zitat Doyle JJ, Neugut AI, Jacobson JS, Grann VR, Hershman DL (2005) Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study. J Clin Oncol 23:8597–8605CrossRefPubMed Doyle JJ, Neugut AI, Jacobson JS, Grann VR, Hershman DL (2005) Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study. J Clin Oncol 23:8597–8605CrossRefPubMed
40.
Zurück zum Zitat Pinder MC, Duan Z, Goodwin JS, Hortobagyi GN, Giordano SH (2007) Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol 25:3808–3815CrossRefPubMed Pinder MC, Duan Z, Goodwin JS, Hortobagyi GN, Giordano SH (2007) Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol 25:3808–3815CrossRefPubMed
41.
Zurück zum Zitat Launay-Vacher V, Gligorov J, Le TC, Janus N, Spano JP, Ray-Coquard I, Oudard S, Pourrat X, Morere JF, Deray G, Beuzeboc P (2010) Prevalence of renal insufficiency in breast cancer patients and related pharmacological issues. Breast Cancer Res Treat 124:745–753CrossRefPubMed Launay-Vacher V, Gligorov J, Le TC, Janus N, Spano JP, Ray-Coquard I, Oudard S, Pourrat X, Morere JF, Deray G, Beuzeboc P (2010) Prevalence of renal insufficiency in breast cancer patients and related pharmacological issues. Breast Cancer Res Treat 124:745–753CrossRefPubMed
Metadaten
Titel
Association between adjuvant chemotherapy and risk of acute kidney injury in elderly women diagnosed with early-stage breast cancer
verfasst von
Shuling Li
Jiannong Liu
Beth A. Virnig
Allan J. Collins
Publikationsdatum
08.12.2016
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 3/2017
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-016-4074-7

Weitere Artikel der Ausgabe 3/2017

Breast Cancer Research and Treatment 3/2017 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.